NASDAQ:OTIC - Otonomy Stock Price, Price Target & More

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy (NASDAQ:OTIC) issued its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.05. The biopharmaceutical company earned $0.27 million during the quarter, compared to analysts' expectations of $0.46 million. Otonomy had a negative net margin of 6,316.88% and a negative return on equity of 58.60%. Otonomy's revenue was down 1.1% compared to the same quarter last year. View Otonomy's Earnings History.

4 equities research analysts have issued 1 year price targets for Otonomy's stock. Their forecasts range from $8.00 to $15.00. On average, they expect Otonomy's stock price to reach $10.00 in the next year. View Analyst Ratings for Otonomy.

Some companies that are related to Otonomy include Kura Oncology (KURA), Achaogen (AKAO), TiGenix (TIG), Progenics Pharmaceuticals (PGNX), Insys Therapeutics (INSY), Achillion Pharmaceuticals (ACHN), Evelo Biosciences (EVLO), Isotechnika Pharma (AUPH), Zealand Pharma (ZEAL), Cytokinetics (CYTK), ObsEva (OBSV), Depomed (DEPO), Concert Pharmaceuticals (CNCE), Dermira (DERM) and Innate Pharma (IPHYF).

Media stories about OTIC stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a news impact score of 0.03 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Otonomy's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.77%), Dimensional Fund Advisors LP (3.68%), JPMorgan Chase & Co. (0.87%), Millennium Management LLC (0.38%), Sofinnova Ventures Inc (0.32%) and A.R.T. Advisors LLC (0.21%). Company insiders that own Otonomy stock include Carl Lebel and Eric J Loumeau. View Institutional Ownership Trends for Otonomy.

OTIC stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Otonomy.

OTIC stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Dimensional Fund Advisors LP, Sofinnova Ventures Inc, Trexquant Investment LP and BlackRock Inc.. View Insider Buying and Selling for Otonomy.

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $4.75.

Otonomy has a market capitalization of $145.25 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]